IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene SRPK1 Ensembl ENSG00000096063 Chromosome 6 Start 35908789 End 35996942
Description Serine/threonine-protein kinase SRPK1 (EC 2.7.11.1)(Serine/arginine-rich protein-specific kinase 1)(SR-protein-specific kinase 1)(SFRS protein kinase 1) [Source:UniProtKB/Swiss-Prot;Acc:Q96SB4]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :REFERENCES :
     HGNC : 11305
     Entrez Gene : 6732
     UCSC : uc003olj.2
     GeneCards : 11305
     RefSeq : NM_003137
     CCDS : CCDS47415.1
     Uniprot : Q96SB4
     Interpro : Q96SB4
     OMIM : 601939
     GeneTests : SRPK1
     CGAP : SRPK1
     PMID : 8208298

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  1031_at  0.90  5.78e-14  1.54e-12  0.92  2.34e-8  2.02e-7
 HG_U133A  202199_s_at  0.41  1.29e-17  8.51e-17  0.81  5.10e-42  1.02e-41
 HG_U133A  202200_s_at  1.06  8.46e-57  6.08e-55  0.97  7.13e-52  1.68e-51
 HG_U133_Plus2  202199_s_at  0.99  2.93e-36  4.04e-34  1.31  1.16e-35  1.09e-33
 HG_U133_Plus2  202200_s_at  0.90  1.13e-27  6.01e-26  0.69  2.70e-11  1.38e-10
 Stanford  19164  1.18  2.17e-4  5.40e-3  0.98  4.70e-3  4.09e-2
 Agilent_HS_21.6K  3307  0.32  3.57e-5  5.09e-4  0.30  2.70e-5  2.63e-4

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  202199_s_at  -0.03  8.48e-1  9.88e-1  0.02  8.55e-1  1.00e+0
 HG_U133A  202200_s_at  -0.38  5.57e-2  7.12e-1  0.17  2.41e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 1031_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 202199_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 202200_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 202199_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 202200_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 19164    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 3307    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
srpk1 human ovarian carcinoma SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line. 11585720 Human
srpk1 human ovarian carcinoma Subsequently, we investigated the role of SRPK1 in cisplatin sensitivity and resistance in human ovarian carcinoma A2780 cells using antisense oligodeoxynucleotides. 11585720 Human
srpk1 testicular germ cell tumors Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1. 15256051 Human
srpk1 tumors Randomly selected GCTs (n = 70) and tumors from patients responding to standard chemotherapy (n = 20) generally showed strong SRPK1 staining. 15256051 Human
srpk1 colonic tumors In the present study, we have established that SRPK1 levels are similarly up-regulated in breast and colonic tumors where its expression increases coordinately with tumor grade. 17332336 Human
srpk1 tumor In the present study, we have established that SRPK1 levels are similarly up-regulated in breast and colonic tumors where its expression increases coordinately with tumor grade. 17332336 Human
srpk1 colonic tumor Targeting SRPK1 for inhibition using small interfering RNA in breast and colonic tumor cell lines in vitro resulted in both increased apoptotic potential and enhanced cell killing after treatment with gemcitabine and cisplatin. 17332336 Human
srpk1 tumor Consequently, we have shown that targeted inhibition of SRPK1 in tumor cells results in reduced phosphorylation of MAPK3, MAPK1, and AKT. 17332336 Human
srpk1 epithelial cancers The up-regulation of SRPK1 in multiple cancers and its ability to regulate multiple relevant signaling pathways provide support for developing agents to inhibit this kinase for possible broad application to treat epithelial cancers. 17332336 Human
srpk1 cancers The up-regulation of SRPK1 in multiple cancers and its ability to regulate multiple relevant signaling pathways provide support for developing agents to inhibit this kinase for possible broad application to treat epithelial cancers. 17332336 Human
srpk1 tumors of the pancreas Using immunohistochemistry, we have localized the expression of a central splicing regulator, serine-arginine protein kinase 1 (SRPK1), to the ductular epithelial cells within human pancreas and have further shown its increased expression in tumors of the 16585209 Human
srpk1 pancreatic tumor Small interfering RNA-mediated down-regulation of SRPK1 in pancreatic tumor cell lines resulted in a dose-dependent decrease in proliferative capacity and increase in apoptotic potential. 16585209 Human
srpk1 tumor Coordinately, the disruption of SRPK1 expression resulted in enhanced sensitivity of tumor cells to killing by gemcitabine and/or cisplatin. 16585209 Human
srpk1 cancer These data support SRPK1 as a new, potential target for the treatment of pancreatic ductular cancer that at present remains largely unresponsive to conventional therapies. 16585209 Human
srpk1 retinoblastoma SRPK1: a cisplatin sensitive protein expressed in retinoblastoma. 17091485 Human
srpk1 rb We investigated the expression of SRPK1 in 63 archival RB and correlated its expression with pathologic staging and exposure to chemotherapy. 17091485 Human
srpk1 tumors The majority of the RB (62/63) were advanced stage (Groups D and E) with intermediate to high risk of treatment failure according to the new international classification for intraocular RB and SRPK1 was reduced in 32/62 (51%) tumors. 17091485 Human
srpk1 rb The majority of the RB (62/63) were advanced stage (Groups D and E) with intermediate to high risk of treatment failure according to the new international classification for intraocular RB and SRPK1 was reduced in 32/62 (51%) tumors. 17091485 Human
srpk1 rb SRPK1 protein expression was reduced in (100%) 8/8 RB that had recurred in the orbit or had metastasized. 17091485 Human
srpk1 rb SRPK1 protein expression is reduced in RB with advanced stage of presentation and this may add to drug resistance mechanisms in RB. 17091485 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.